Following the successful completion of the acquisition of our first brand, Onsolis, we are pleased to announce that Adalvo will start supply of the product.
The brand is an opioid analgesic, indicated in the management of persistent breakthrough pain, in cancer patients who have already received and are tolerant to opioid therapy for their underlying cancer pain.
Adalvo is the sole and exclusive owner of the brand and has obtained full rights on the product, taking over all existing business and all market authorizations, globally, including the US.
Our business remains fueled by our passion for relentless commitment to the partner network that we serve, and we will continue to bring high value assets to our portfolio, now venturing also within the branded product domain